Patents by Inventor Zhaoyin Wang

Zhaoyin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7169809
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: January 30, 2007
    Assignee: Merck Frosst Company
    Inventors: Carl Berthelette, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Patent number: 7144913
    Abstract: Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: December 5, 2006
    Assignee: Merck Frosst Canada & Co.
    Inventors: Zhaoyin Wang, Christian Beaulieu, Claude Dufresne, Daniel Guay, Yves LeBlanc
  • Patent number: 7060715
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: June 13, 2006
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Publication number: 20060069148
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Application
    Filed: November 4, 2005
    Publication date: March 30, 2006
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Patent number: 7019022
    Abstract: The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: March 28, 2006
    Assignee: Merck Frosst Canada & Co.
    Inventors: Christian Beaulieu, Daniel Guay, Zhaoyin Wang, Robert Zamboni
  • Publication number: 20060058363
    Abstract: The invention encompasses novel compounds of Formula (I) and Formula (II), which are nitric oxide-releasing prodrugs useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I) or Formula (II). The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.
    Type: Application
    Filed: October 21, 2003
    Publication date: March 16, 2006
    Inventors: Zhaoyin Wang, Robert Young, Robert Zamboni
  • Publication number: 20050261245
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.
    Type: Application
    Filed: July 24, 2003
    Publication date: November 24, 2005
    Inventors: Carl Berthelette, Nicholas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang, Robert Young, Claude Dufresne
  • Publication number: 20050154044
    Abstract: The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion.
    Type: Application
    Filed: December 8, 2004
    Publication date: July 14, 2005
    Inventors: Christian Beaulieu, Daniel Guay, Zhaoyin Wang, Robert Zamboni
  • Publication number: 20050124680
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Application
    Filed: January 22, 2003
    Publication date: June 9, 2005
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Publication number: 20050009875
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Application
    Filed: August 11, 2004
    Publication date: January 13, 2005
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Gauthier
  • Publication number: 20040180934
    Abstract: Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.
    Type: Application
    Filed: October 15, 2003
    Publication date: September 16, 2004
    Inventors: Zhaoyin Wang, Christian Beaulieu, Claude Dufresne, Daniel Guay, Yves LeBlanc
  • Publication number: 20040176331
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Application
    Filed: March 1, 2004
    Publication date: September 9, 2004
    Inventors: Carl Berthelette, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Publication number: 20030158246
    Abstract: Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.
    Type: Application
    Filed: January 21, 2003
    Publication date: August 21, 2003
    Inventors: Carl Berthelette, Nicolas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang
  • Patent number: 6596736
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: July 22, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Patent number: 6583126
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: June 24, 2003
    Assignee: Merck Erosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Scheigetz John, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michael Boyd, Zhaoyin Wang
  • Publication number: 20030065011
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: October 30, 2001
    Publication date: April 3, 2003
    Applicant: Merck Frosst Canada & Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
  • Patent number: 6498151
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: December 24, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Patent number: 6486142
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Patent number: 6486141
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related conditions.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Cheuk Kun Lau, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Chun Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang
  • Patent number: 6486194
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien